Assembly Biosciences, Inc. (NASDAQ:ASMB) Insider Nicole S. White Sells 1,255 Shares of Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) insider Nicole S. White sold 1,255 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $12.71, for a total value of $15,951.05. Following the sale, the insider now owns 13,025 shares in the company, valued at approximately $165,547.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Assembly Biosciences Price Performance

Shares of ASMB stock opened at $13.27 on Thursday. Assembly Biosciences, Inc. has a fifty-two week low of $7.69 and a fifty-two week high of $20.04. The stock’s 50-day simple moving average is $13.17 and its 200-day simple moving average is $11.15.

Wall Street Analysts Forecast Growth

ASMB has been the topic of several research analyst reports. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st. StockNews.com raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th.

Hedge Funds Weigh In On Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned about 0.08% of Assembly Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.